Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Valeria SebastianiChristine A Iacobuzio-Donahue

Abstract

Gemcitabine is considered the standard first-line therapy for patients with advanced pancreatic cancer. More recent strategies have focused on improving the efficacy of gemcitabine by either improving the method of delivery or by combining gemcitabine with other non-cross-resistant chemotherapy agents or with small-molecule drugs. However, the clinical benefits, response rates, and duration of responses have been modest. Deoxycytidine kinase (dCK) is the rate-limiting enzyme involved in the metabolism of gemcitabine. The expression of dCK has been postulated to be correlative of gemcitabine resistance. We determined the relationship of dCK immunohistochemical protein expression and/or genetic status of dCK in a panel of human pancreatic cancer tissues and pancreatic cancer cell lines and determined the relationship of these variables to the clinical outcome of patients treated with gemcitabine. We report that dCK protein expression is expressed in the majority of pancreatic cancers analyzed (40 of 44 cases, 91%) and showed a range of labeling intensities ranging from 1+ (labeling weaker in intensity than normal lymphocytes present in same section) to 3+ (labeling greater in intensity than normal lymphocytes present in same sect...Continue Reading

References

May 23, 1998·Advances in Experimental Medicine and Biology·C J van MoorselG J Peters
Nov 7, 1998·The Journal of Biological Chemistry·P HatzisI Talianidis
Jul 28, 2001·Japanese Journal of Cancer Research : Gann·T ObataT Sasaki
Oct 31, 2002·European Journal of Haematology·Marjan J T VeugerRenée M Y Barge
Mar 12, 2003·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·C L van der WiltG J Peters
Mar 22, 2003·Expert Review of Anticancer Therapy·Basil F El-Rayes, Philip A Philip
Sep 15, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Caio M Rocha LimaLangdon L Miller
Oct 27, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jennifer SpratlinJohn R Mackey
Jan 22, 2005·CA: a Cancer Journal for Clinicians·Ahmedin JemalMichael J Thun
Jan 22, 2013·CA: a Cancer Journal for Clinicians·Rebecca SiegelAhmedin Jemal

❮ Previous
Next ❯

Citations

Apr 6, 2011·Breast Cancer Research and Treatment·Ernst-Jan GeutjesRené Bernards
May 6, 2010·Targeted Oncology·Luca Toschi, Federico Cappuzzo
Nov 11, 2009·Medical Oncology·M CandelariaA Dueñas-González
Nov 28, 2013·Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [et Al.]·Beatrice Mohelnikova-Duchonova, Bohuslav Melichar
Feb 10, 2011·Nature Reviews. Clinical Oncology·Joseph CiccoliniNicolas André
Dec 22, 2011·The Pharmacogenomics Journal·M A Lowery, E M O'Reilly
Feb 7, 2009·Proceedings of the National Academy of Sciences of the United States of America·Rachel E LaingCaius G Radu
Jun 17, 2008·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Neslihan Aygun KocabasMatthew M Ames
Jan 20, 2007·Annals of Surgical Oncology·Yoshiyasu MitaYoshikazu Kuroda
Jan 1, 2009·OncoTargets and Therapy·Luca Toschi, Federico Cappuzzo
Dec 24, 2008·Pharmacogenomics·Romano DanesiRaffael Rosell
Aug 24, 2013·International Journal of Molecular Sciences·Hoin KangEun Kyung Lee
Aug 3, 2013·Biomarkers in Medicine·Lars Petter Jordheim, Charles Dumontet
Jan 23, 2013·Drugs & Aging·Raphaël MaréchalJean-Luc Van Laethem
Feb 9, 2013·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Tingting WengMichael R Blackburn
Dec 25, 2015·Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [et Al.]·Kyoichi TakaoriUNKNOWN IAP/EPC study group on the clinical managements of pancreatic cancer
Oct 16, 2009·Expert Review of Anticancer Therapy·Raphaël Maréchal, Jean-Luc Van Laethem
Oct 15, 2010·Expert Review of Anticancer Therapy·Rizwan SheikhRay McDermott
Jun 12, 2009·Drug Metabolism Reviews·Andrea WongFederico Innocenti
Mar 13, 2009·Expert Opinion on Investigational Drugs·M Wasif SaifAlan J Husband
Mar 20, 2012·Cancer Letters·Sau Wai HungRajgopal Govindarajan
Feb 12, 2011·HPB : the Official Journal of the International Hepato Pancreato Biliary Association·Jill E SheaCourtney L Scaife
Mar 5, 2016·Future Oncology·Kalyan C Mantripragada, Howard Safran
Dec 17, 2015·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Zhen-Hua WuXi-Chun Hu
Dec 2, 2008·Gastroenterology·Andrew H Ko, Margaret A Tempero
Oct 21, 2010·CA: a Cancer Journal for Clinicians·Rodolphe Taby, Jean-Pierre J Issa
Oct 1, 2011·Wiley Interdisciplinary Reviews. RNA·Jonathan R Brody, Gregory E Gonye

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.